News

Keep Up to date with our latest news and press releases

ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers

December 1, 2021 – (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received Breakthrough Device designation from the Centers for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for its ZetaMet™ technology.

Zetagen Therapeutics, Inc. Announces European Patent for the Treatment of Stimulating Bone Growth

April 28, 2021 – (Syracuse, New York) - Zetagen Therapeutics, Inc. a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions today announced that the European Patent Office issued Patent. No. 3148517 to the Company.

Zetagen Therapeutics, Inc. Receives Australian Patent Issuance for Treatment of Stimulating Bone Growth

July 23, 2020 – (Syracuse, New York) - private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and orthopedic interventions, announced today that the Australian Government has issued Patent No. 2015267006 to the Company. The patent, entitled Composition and Methods to Promote Bone Formation, covers the use of methods for stimulating bone growth using the Company’s small molecule, ZetaMet™.

Zetagen Therapeutics, Inc. Secures $5.34 Million in Series A Funding to Accelerate Clinical Work

February 6, 2020 – (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced the close of $5.34M Series A funding round. The financing will accelerate the growth of the Company’s ongoing clinical programs for ZetaMet™

Zetagen Therapeutics, Inc. Awarded $225,000 USD Grant from NIAMS for Phase I Study of Novel Osteoinductive Lumbar Fusion Implant for Small Molecule-Based

September 11, 2019 – (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today its award of $225,000 USD from the National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zetagen Therapeutics, Inc. Receives Patent for Regulation of Bone Growth and Bone Degradation Using Small-Molecule

April 23, 2019 – (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biotechnology company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 102656437 to the Company.

Zetagen Therapeutics, Inc. Receives Patents for Methods in Stimulating Bone Growth Using Small-Molecule

February 19, 2019– (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and orthopedic interventions, announced today that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 10208306 and the South African Patent Office issued PCT. 201700029 to the Company.

Zetagen Therapeutics, Inc. Awarded $300,000 USD Grant from the National Cancer Institute (NCI) for Phase I Study of Novel, Adjuvant Implant for Post-Metastatic Skeletal Lesions

September 5, 2018– (Syracuse, New York) - Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today its award of a $300,000 (USD) grant from the National Cancer Institute of the National Institutes of Health (NIH).